Health Care

Explore how Incyte’s insider sale and pipeline strategy reveal the future of biotech commerce, from value‑based pricing to accelerated approvals and investor confidence.

Novocure insider sale: a routine RSU‑driven sell‑to‑cover at $15.77 shows no major market impact; focus on pipeline milestones for long‑term value.

Progyny CFO’s recent share sale shows routine insider activity—insights into liquidity, governance, and long‑term confidence in the company’s growth prospects.

Ber Gerard’s May 14 sale of Lantheus shares shows no market shift—insider confidence stays high, and the firm’s strong diagnostics pipeline suggests a good entry point near $100 before a potential rebound toward its 52‑week high.

Insider Gordon’s recent 298‑share purchase of Veeva Systems signals growing confidence in the company’s growth, reinforcing a bullish outlook ahead of earnings.

Insider sales of restricted shares by top executives raise questions about the company’s management sentiment, but solid fundamentals suggest the moves may be routine liquidity or tax planning rather than a shift in outlook.

Insider selling spikes at Natera (NTLA) – what it signals for shareholders. Learn how executive divestments, valuation gaps, and litigation risk could affect the share price.

United Therapeutics insider trades show disciplined 10 b‑5(1) management—steady growth, solid pipeline, and no market‑timing red flags.

Insider buying surges at Avita Medical (CDI) as executives purchase thousands of shares, signaling confidence amid a 27% YTD decline.

Insider selling at TEMPUS AI signals portfolio rebalancing, not distress—focus on the company’s AI‑driven precision‑medicine roadmap and upcoming milestones for potential upside.